Exposure of Ochratoxins Might Affect the Therapeutic Window of Ear-Nose-Throat Treatment Drug Diphenidol

Ear, nose and throat (ENT, otolaryngology) diseases threaten the health of humans, and efficient therapy of ENT diseases is very important and necessary. Vomiting is a typical ENT-disease, and-it strongly needs the suitable drug for therapy. Diphenidol is an antiemetic agent clinically used to treat vomiting. UDP-glucuronosyltransferase (UGT) 2B7 is the major drug-metabolizing enzyme (DME) catalyzing the glucuronidation metabolism of diphenidol. The present study tried to demonstrate that exposure of ochratoxins might affect the therapeutic window of ear-nose-throat treatment drug diphenidol through evaluating the imbibition of ochratoxins on the activity of UGT2B7 using in silica method. Chem draw software was used to draw the chemical structure of ochratoxins, and homology modeling method was employed to get the 3D structure of UGT2B7. Docking results showed that hydrogen bonds and hydrophobic interactions significantly contributed to the strong binding of ochratoxins towards the activity cavity of UGT2B7. In conclusion, exposure of ochratoxins might affect the therapeutic window of ear nose throat treatment drug diphenidol.